tweenvest

Attovia Therapeutics, Inc. (NasdaqGM: ATTO)

Health Care · Biotechnology · US

$15.13

-4.30% today · -30.9% 1Y

Public summary
A free snapshot of Attovia Therapeutics, Inc., with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app

Attovia Therapeutics, Inc. (NasdaqGM: ATTO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $690.70M and employs 44 people.

Over the last twelve months the share price has lost 30.9%, trading between 12.94 and 28.00.

Tweenvest scores Attovia Therapeutics, Inc. across four factors: quality 45/100, value 76/100. Its strongest factor is value.

ATTO price history

Aug 7, 2026 · 20.17Weekly closes 13.73 – 25.55Nov 13, 2026 · 15.13

Key figures

Market cap
$690.70M
Revenue (TTM)
$1.44M
P/E
-9.81
EPS
-16.97
Dividend yield
—
Beta (5Y)
—
52-week high
$28.00
52-week low
$12.94
Avg volume (3M)
—
Shares outstanding
45.65M
Employees
44
Next earnings
—

About Attovia Therapeutics, Inc.

A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.

ISIN
US04987L1026
Founded
2022
Listed since
Aug 5, 2026
Exchange
Nasdaq Global Market
Currency
USD
CompanyMarket capPriceDay
Solid Biosciences Inc.NasdaqGS: SLDB$708.73M$6.35+1.93%
CARsgen Therapeutics Holdings LimitedSEHK: 2171$699.39MHK$9.76-3.37%
Nuvectis Pharma, Inc.NasdaqCM: NVCT$696.03M$20.24+0.05%
Achieve Life Sciences, Inc.NasdaqCM: QUIT$695.42M$6.32+0.48%
4D Molecular Therapeutics, Inc.NasdaqGS: FDMT$689.52M$12.23+0.95%
Prime Medicine, Inc.NasdaqGM: PRME$681.67M$3.82-0.13%
Kura Oncology, Inc.NasdaqGS: KURA$674.39M$7.34-2.00%
ArriVent BioPharma, Inc.NasdaqGM: AVBP$672.92M$13.01-0.46%

Browse every Biotechnology company →